MAAT INDEX

CLAIM #3398 · Abbott Laboratories (ABT) · 2026Q2 earnings call · Jul 16, 2026 · due Dec 31, 2026

our deal model, that we put together to support the acquisition, for 2026 had mid-teens. I feel confident that we will achieve that.

Robert Ford · CEO

PENDING
graded after results covering Dec 31, 2026 are reported

How to check this claim

Look at: Metric implied by 'mid-teens' in the acquisition deal model for 2026 (likely growth rate or margin, as disclosed by company) — presumed to be a percentage growth/margin figure referenced in the deal model

It came true if: 2026 figure for the referenced metric falls within 14%-17% (mid-teens range)

Where: Company earnings release, 10-K, or management commentary disclosing 2026 results for the metric referenced

Verify independently

SEC filings for ABT · Claim quote is verbatim from the 2026Q2 earnings call.